TY - JOUR
T1 - ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma
AU - Kim, Heejin
AU - Choi, Joo Yeon
AU - Rah, Yoon Chan
AU - Ahn, Jae Cheul
AU - Kim, Hyunchul
AU - Jeong, Woo Jin
AU - Ahn, Soon Hyun
N1 - Funding Information:
We are grateful for the support provided for this study by the SNUBH Research Fund (Grant Number: 02-2016-014 , 11-2011-026 ) and the SK Telecom Health Connect Research Fund (Grant Number: 06-2014-166 ).
Funding Information:
We are grateful for the support provided for this study by the SNUBH Research Fund (Grant Number: 02-2016-014, 11-2011-026) and the SK Telecom Health Connect Research Fund (Grant Number: 06-2014-166).
Publisher Copyright:
© 2019 Elsevier Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4
Y1 - 2020/4
N2 - Objective: We aimed to identify the prognostic factors in head and neck squamous cell carcinoma (HNSCC) by using gene expression analysis and candidate biomarkers for adjuvant therapy. Study Design: Complementary DNA (cDNA) microarray analysis was performed by using samples from 8 patients, who had died as a result of fulminant recurrence shortly after postoperative radiation therapy, and the results were compared with those from patients with HNSCC of similar stage, but without recurrence. Tissue microarray and immunohistochemistry of samples from 69 patients with oral cavity squamous cell carcinoma indicated ErbB3 to be a prognostic marker, and its expression was analyzed in the HNSCC cell lines. Sapitinib was tested as a concurrent inhibitor of EGFR, ErbB2, and ErbB3. In 15 mice, tumor xenograft was implanted at the lateral tongue, and tumor growth was evaluated. Results: ErbB3 overexpression in patients with treatment-resistant HNSCC was associated with relapse-free survival, disease-free survival, and overall survival (P = .018, P = .006, and P = .003, respectively). In the HNSCC cell line, ErbB2 and ErbB3 overexpression was inhibited by postoperative adjuvant therapy with sapitinib, which was also seen to improve survival in an animal model. Conclusions: ErbB3 overexpression predicts a poor clinical outcome. Sapitinib was shown to be an effective inhibitor in the HNSCC cell line and animal models of cancer but with no statistical significance. Further studies with larger groups are needed to better support these results.
AB - Objective: We aimed to identify the prognostic factors in head and neck squamous cell carcinoma (HNSCC) by using gene expression analysis and candidate biomarkers for adjuvant therapy. Study Design: Complementary DNA (cDNA) microarray analysis was performed by using samples from 8 patients, who had died as a result of fulminant recurrence shortly after postoperative radiation therapy, and the results were compared with those from patients with HNSCC of similar stage, but without recurrence. Tissue microarray and immunohistochemistry of samples from 69 patients with oral cavity squamous cell carcinoma indicated ErbB3 to be a prognostic marker, and its expression was analyzed in the HNSCC cell lines. Sapitinib was tested as a concurrent inhibitor of EGFR, ErbB2, and ErbB3. In 15 mice, tumor xenograft was implanted at the lateral tongue, and tumor growth was evaluated. Results: ErbB3 overexpression in patients with treatment-resistant HNSCC was associated with relapse-free survival, disease-free survival, and overall survival (P = .018, P = .006, and P = .003, respectively). In the HNSCC cell line, ErbB2 and ErbB3 overexpression was inhibited by postoperative adjuvant therapy with sapitinib, which was also seen to improve survival in an animal model. Conclusions: ErbB3 overexpression predicts a poor clinical outcome. Sapitinib was shown to be an effective inhibitor in the HNSCC cell line and animal models of cancer but with no statistical significance. Further studies with larger groups are needed to better support these results.
UR - http://www.scopus.com/inward/record.url?scp=85079530157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079530157&partnerID=8YFLogxK
U2 - 10.1016/j.oooo.2019.12.006
DO - 10.1016/j.oooo.2019.12.006
M3 - Article
C2 - 32081558
AN - SCOPUS:85079530157
VL - 129
SP - 377
EP - 387
JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
SN - 2212-4403
IS - 4
ER -